Abstract
To date, treatment options for severe COVID-19 remain limited and there is currently no effective drug or vaccine for the treatment or prevention of specific SARS-CoV-2 to treat critically ill patients. A new treatment strategy, in addition to antiviral therapy alone, may be required to have a significant impact on clinical outcomes. Immunomodulatory therapy to downregulate cytokine shock may provide information on the treatment of COVID-19. Combined use of an immunomodulatory agent with an antiviral agent may give doctors more time to provide supportive therapy to patients with COVID-19. In this review of the literature, the roles of several anti-inflammatory drugs were reviewed to explore their effectiveness in the fight against SARS-CoV-2.